I focus on identifying and evaluating external therapeutic and technology platform opportunities that can contribute to Calico’s research and development efforts in aging and related diseases. I am also responsible for negotiating agreements that provide Calico with the necessary rights to further develop these opportunities.
Before Calico, I was the Executive Director of Business Development at Alexion Pharmaceuticals, where I helped build the Business Development group and led many licensing and M&A transactions that diversified Alexion’s pipeline of drugs for ultra-orphan diseases. Prior to Alexion, I spent 10 years at Genentech in the Business Development group focusing on oncology, as well as in the Market Planning group, where I helped to plan the commercial launch of Xolair for severe allergic asthma. Before Genentech, I was a consultant in health care practice at the management consulting firm Booz Allen and Hamilton.